compound 52 [PMID: 36749735]   Click here for help

GtoPdb Ligand ID: 12412

Compound class: Synthetic organic
Comment: This compound is an inhibitor of EGFR with double mutations at L858R (activating mutation) and T790M (gatekeeper resistance mutation) [1]. It was designed to combat advanced tumours that are driven by this mutated kinase, whilst sparing function of the wild type EGFR.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 81.56
Molecular weight 498.62
XLogP 2.53
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=CC(=C1)C2=C(C3=CC=CC=C3)OC4=C2C(=NC=N4)NC(C)C)N(C)CCN(C)C
Isomeric SMILES CN(CCN(C)C)C=1C(NC(C=C)=O)=CC(=CC1)C2=C(C3=CC=CC=C3)OC4=C2C(NC(C)C)=NC=N4
InChI InChI=1S/C29H34N6O2/c1-7-24(36)33-22-17-21(13-14-23(22)35(6)16-15-34(4)5)25-26-28(32-19(2)3)30-18-31-29(26)37-27(25)20-11-9-8-10-12-20/h7-14,17-19H,1,15-16H2,2-6H3,(H,33,36)(H,30,31,32)
1. Li MC, Coumar MS, Lin SY, Lin YS, Huang GL, Chen CH, Lien TW, Wu YW, Chen YT, Chen CP et al.. (2023)
Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
J Med Chem, 66 (4): 2566-2588. [PMID:36749735]